by Medical University of South Carolina This figure depicts the two major T-cell co-stimulation pathways, ICOS and CD28, targeted by the new drug candidate ALPN-101 as compared to CTLA-4-Fc CD28/B7 pathway inhibitors (abatacept and belatacept) for the treatment of graft-versus-host disease. A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D.,...
